Approvals for oncology drugs is around 5% - less than half compared to other treatment areas. The rate of failure is increasing, especially beyond Phase II trials.
New regulatory requirements for the development of regenerative medicine in oncology demands stakeholders to be even more conscious of safety throughout the development process.
Recently, drug development in Asia has become increasingly active. Preparedness to differences between Asian countries is critical to development.
Our Consultation Services
Responding to All Intractable Cancers
Led by experts with over 20 years of working experience in clinical trials for oncology, over 90% of our projects have achieved milestones in oncology.
We have implemented a one-of-a-kind certification program for developing Oncology specialists under the guidance of Dr. Nagahiro Saijo (globally recognized KOL). CRAs who have obtained Remedy’s specialized certifications are assigned to clinical trials.
Our MSLs are highly qualified with extensive on-site experience and expertise in Oncology.